Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
49 studies found for:    weill AND genetic medicine | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy
Condition: Peanut Allergy
Intervention:
2 Recruiting Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
Conditions: Batten Disease;   Late Infantile Neuronal Lipofuscinosis
Intervention:
3 Recruiting COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function
Conditions: COPD;   Smoking
Interventions: Other: Cohort I;   Other: Cohort II
4 Recruiting Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Conditions: Chronic Obstructive Pulmonary Disease (COPD);   Smoking;   Smoking Cessation
Intervention:
5 Recruiting Integrative-omics of the Disordered COPD Small Airway Epithelium
Conditions: Smoking;   COPD
Intervention:
6 Recruiting Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.
Conditions: Lung Disease;   Inflammation;   Lung Cancer;   Sarcoidosis
Intervention:
7 Recruiting HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium
Conditions: HIV;   COPD;   Emphysema;   Smoking
Intervention:
8 Recruiting HIV-related Accelerated Aging of the Airway Epithelium
Conditions: HIV;   COPD;   Chronic Obstructive Pulmonary Disease;   Smoking
Intervention:
9 Recruiting Doxycycline for COPD in HIV-Infected Patients
Conditions: HIV;   Chronic Obstructive Pulmonary Disease (COPD);   Emphysema
Interventions: Drug: Doxycycline;   Drug: Placebo (sugar pill)
10 Recruiting Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
Condition: Cocaine Dependence
Interventions: Biological: dAd5GNE Vaccine;   Biological: Placebo
11 Recruiting Alternate Nicotine Delivery Systems and Airway Epithelial Biology
Conditions: Smoking;   Smoking Cessation
Intervention:
12 Recruiting Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis
Conditions: Batten Disease;   Late-Infantile Neuronal Ceroid Lipofuscinosis
Interventions: Genetic: AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies;   Genetic: AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies
13 Recruiting AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis
Conditions: Late Infantile Neuronal Ceroid Lipofuscinosis;   Batten Disease
Intervention: Biological: AAVrh.10CUCLN2
14 Recruiting Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
Condition: Thromboembolism
Interventions: Genetic: Pharmacogenetic;   Drug: Target INR 1.8
15 Recruiting Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies
Condition: Lymphoma
Intervention: Other: Non Interventional
16 Recruiting International Study to Predict Optimised Treatment - in Depression
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Sertraline;   Drug: Venlafaxine-XR
17 Recruiting Familial Myeloproliferative Disorders
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Idiopathic Myelofibrosis
Intervention:
18 Recruiting Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
Condition: Posttraumatic Stress Disorder
Interventions: Drug: DCS;   Other: Placebo
19 Recruiting Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Condition: Myelodysplastic Syndrome
Interventions: Drug: vadastuximab talirine;   Drug: Azacitidine;   Drug: Placebo (for 33A)
20 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Refractory Malignant Neoplasm;   Solid Neoplasm
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.